For non-metastasized patients, the latest European Neuroendocrine Tumor Society (ENETS) guidelines also discriminate between “low-G2” and “high-G2” panNET without providing cutoff values, suggesting different treatment responses within this patient population.1 Furthermore, several studies describe a higher discriminating capacity when G1 and G2 panNET are divided by a Ki67 cutoff of 5% instead of 3% to predict disease progression.5,24,25. The gene discussed is MKI67; the disease is neoplasm.